Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of botulinum toxin in treating scleroderma-associated raynaud’s phenomenon: a systematic review and meta-analysis

  • Research Letter
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data availability

All data relevant to this study are included in this article.

References

  1. Cappelli L, Wigley FM (Aug. 2015) Management of Raynaud Phenomenon and Digital Ulcers in Scleroderma. Rheumatic Disease Clin North Am 41(3):419–438. https://doi.org/10.1016/j.rdc.2015.04.005

  2. Medina S et al (2018) Botulinum toxin type A in the treatment of Raynaud’s phenomenon: A three-year follow-up study, Eur J Rheumatol, vol. 5, no. 4, pp. 224–229, https://doi.org/10.5152/eurjrheum.2018.18013Fiakos G, Kuang Z, Lo E. Improved skin regeneration with acellular fish skin grafts. Engineered Regeneration. 2020;1:95–101. doi:10.1016/j.engreg.2020.09.002

  3. Neumeister MW et al (2009) Botox Therapy for Ischemic Digits, Plast Reconstr Surg, vol. 124, no. 1, pp. 191–201, doi: 10.1097/PRS.0b013e3181a80576.Lima Júnior EM, Moraes Filho MO de, Forte AJ,. Pediatric Burn Treatment Using Tilapia Skin as a Xenograft for Superficial Partial-Thickness Wounds: A Pilot Study. Journal of Burn Care & Research. Published online August 26, 2019. https://doi.org/10.1093/jbcr/irz149

  4. Ennis D, Ahmad Z, Anderson MA, Johnson SR, Botulinum toxin in the management of primary and secondary Raynaud’s phenomenon, (2021) https://doi.org/10.1016/j.berh.2021.101684.W. Du, M. Zhou, C. Zhang, and Q. Sun, The efficacy of botulinum toxin A in the treatment of Raynaud’s phenomenon in systemic sclerosis: A randomized self-controlled trial, Dermatol Ther, vol. 35, no. 7, Jul. 2022, doi: 10.1111/dth.15529

  5. Du W, Zhou M, Zhang C, Sun Q (Jul. 2022) The efficacy of botulinum toxin A in the treatment of Raynaud’s phenomenon in systemic sclerosis: a randomized self-controlled trial. Dermatol Ther 35(7). https://doi.org/10.1111/dth.15529

  6. Bello et al (2017) The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud’s phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol 69(8):1661–1669. https://doi.org/10.1002/art.40123

  7. Jokar MH et al (2022) Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis. Reumatologia 60(6):392–398. https://doi.org/10.5114/reum.2022.120757

  8. Senet P et al (2023) Efficacy and safety of botulinum toxin in adults with Raynaud’s phenomenon secondary to systemic sclerosis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 75(3):459–467. https://doi.org/10.1002/art.42342

  9. Seyedmardani SM et al (2022) Evaluation of botulinum toxin type A and its potential effect on exacerbated Raynaud’s phenomenon in hospitalized scleroderma patients. Curr Rheumatol Rev 18(1):48–57. https://doi.org/10.2174/1573397117666211012105611

Download references

Funding

Open Access funding provided by the open access agreement between Egypt and springer.

Author information

Author notes

  1. Mohamed Abo Zeid and Amr Elrosasy are considered joint first author.

Authors and Affiliations

  1. Faculty of Medicine, Cairo University, Cairo, Egypt

    Amr Elrosasy

  2. Faculty of Medicine, Tanta University, Tanta, Egypt

    Mohamed Abo Zeid & Mohamed A. Elzeftawy

  3. University of medicine and pharmacy Grigore T. Popa, Ia?i, Romania

    Shirin cadri

  4. faculty of medicine, Ain shams university, Ain shams, Egypt

    Belal M. Fahmy

  5. Faculty of Medicine, Aswan University, Aswan, Egypt

    Fatma Mohammed

  6. Faculty of Medicine, South Valley University, Qena, Egypt

    Alaa Ramadan

  7. Medical research group of Egypt (MRGE), Negida Academy, Arlington, MA, US

    Amr Elrosasy

Authors
  1. Amr Elrosasy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohamed Abo Zeid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shirin cadri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Belal M. Fahmy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohamed A. Elzeftawy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fatma Mohammed
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alaa Ramadan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization and design of the work: [Amr Elrosasy, Alaa Ramadan]; Acquisition of the data: [Mohamed Abo Zeid, Shirin Cadri, Belal.M Fahmy, Mohamed A. Elzeftawy]; Formal analysis: [Amr Elrosasy]; Interpretation of data: [Fatma Mohammed]; Drafting the work: [Shirin Cadri, Belal. M Fahmy, Mohamed A. Elzeftawy]; Revising the work critically: [Amr Elrosasy, Alaa Ramadan, Mohamed Abo Zeid, Fatma Mohammed]; Final approval of the version to be published and agreement to be accountable for all aspects of the work: [Amr Elrosasy, Alaa Ramadan, Mohamed Abo Zeid, Shirin Cadri, Belal.M Fahmy, Mohamed A. Elzeftawy, Fatma Mohammed] Funding acquisition: [STDS].

Corresponding author

Correspondence to Mohamed Abo Zeid.

Ethics declarations

Ethics approval

Not applicable.

Competing interests

The authors declare that there is no conflict of interest regarding the publication of this article.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elrosasy, A., Abo Zeid, M., cadri, S. et al. Efficacy and safety of botulinum toxin in treating scleroderma-associated raynaud’s phenomenon: a systematic review and meta-analysis. Arch Dermatol Res 316, 122 (2024). https://doi.org/10.1007/s00403-024-02864-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00403-024-02864-x

Keywords

Search

Navigation